RA Capital Management 13F holdings, Q1 2018
Holdings as of March 31, 2018 · filings on SEC EDGAR · latest filing →
RA Capital Management disclosed 31 US equity positions worth $1.3bn in its Q1 2018 13F filing. The largest position was WVE at 23.1% of the reported book, followed by ASND and AVEXIS INC. Against the Q4 2017 filing, it opened 9 new positions, added to 2 and reduced 10 among the top 31 holdings.
What did RA Capital Management own in Q1 2018? Top 31 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q4 2017 |
|---|---|---|---|---|---|---|---|
| 1 | WVE WAVE LIFE SCIENCES LTD | Healthcare | 23.1% | $301.2m | 7,512,049 | 0% | held |
| 2 | ASND ASCENDIS PHARMA A S | Healthcare | 21.2% | $277.3m | 4,240,536 | -24% | reduced |
| 3 | AVEXIS INC | 9.7% | $127.1m | 1,028,289 | -12% | reduced | |
| 4 | MYOVANT SCIENCES LTD | 4.6% | $60.2m | 2,830,455 | 0% | held | |
| 5 | SG7 SAGE THERAPEUTICS INC | 4.4% | $56.9m | 353,133 | -22% | reduced | |
| 6 | INFLARX NV | 3.6% | $46.7m | 1,620,653 | -44% | reduced | |
| 7 | ZOGENIX INC | 3.5% | $45.9m | 1,145,268 | 0% | held | |
| 8 | DICERNA PHARMACEUTICALS INC | 2.9% | $37.6m | 3,933,489 | -21% | reduced | |
| 9 | SCPHARMACEUTICALS INC | 2.7% | $35.4m | 2,857,143 | 0% | held | |
| 10 | ENDOCYTE INC | 2.7% | $35.3m | 3,881,793 | 15% | added | |
| 11 | TGTX TG THERAPEUTICS INC | Healthcare | 2.7% | $35.1m | 2,472,344 | – | new |
| 12 | KALA PHARMACEUTICALS INC | 2.6% | $33.5m | 2,113,236 | 0% | held | |
| 13 | BCRX BIOCRYST PHARMACEUTICALS | Healthcare | 2.6% | $33.3m | 6,984,692 | 0% | held |
| 14 | RA PHARMACEUTICALS INC | 1.6% | $20.5m | 3,851,808 | 185% | added | |
| 15 | SLDB SOLID BIOSCIENCES INC | 1.5% | $20.2m | 2,689,444 | – | new | |
| 16 | APELLIS PHARMACEUTICALS INC | 1.5% | $19.9m | 900,000 | 0% | held | |
| 17 | CLEARSIDE BIOMEDICAL INC | 1.3% | $16.4m | 1,525,000 | – | new | |
| 18 | AVEO PHARMACEUTICALS INC | 1.1% | $14.7m | 5,062,759 | 0% | held | |
| 19 | 4XC1 KALVISTA PHARMACEUTICALS INC | 1.0% | $13.7m | 1,441,070 | 0% | held | |
| 20 | CATALYST BIOSCIENCES INC | 1.0% | $13.3m | 514,917 | – | new | |
| 21 | IOVA IOVANCE BIOTHERAPEUTICS INC | Healthcare | 0.9% | $11.1m | 659,059 | – | new |
| 22 | SPRO SPERO THERAPEUTICS INC | Healthcare | 0.8% | $10.6m | 741,647 | -39% | reduced |
| 23 | BIOHAVEN PHARMACTL HLDG CO LTD | 0.7% | $9.4m | 363,636 | -82% | reduced | |
| 24 | VKTX VIKING THERAPEUTICS INC | Healthcare | 0.7% | $8.9m | 2,029,396 | – | new |
| 25 | SUNESIS PHARMACEUTICALS INC | 0.5% | $6.7m | 2,471,456 | -20% | reduced | |
| 26 | KRYS KRYSTAL BIOTECH INC | Healthcare | 0.4% | $5.0m | 496,071 | -29% | reduced |
| 27 | GLYCOMIMETICS INC | 0.3% | $4.1m | 253,547 | – | new | |
| 28 | PROTEON THERAPEUTICS INC | 0.3% | $3.3m | 1,337,462 | 0% | held | |
| 29 | G1 THERAPEUTICS INC | 0.1% | $1.5m | 40,000 | -75% | reduced | |
| 30 | EDGE THERAPEUTICS INC | 0.0% | $337.0k | 285,491 | – | new | |
| 31 | CTI BIOPHARMA CORP | 0.0% | $222.0k | 56,951 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.